Incyte (INCY) Income from Continuing Operations (2010 - 2026)
Incyte's (INCY) quarterly Income from Continuing Operations came in at 585605000.0 in Q2 2026, up 44.59% YoY from 404999000.0 in Q2 2025, and up 93.06% on a QoQ basis from 303330000.0 in Q1 2026.
Incyte (INCY) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Income from Continuing Operations data on file, last reported at 585605000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 44.59% year-over-year to 585605000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1612383000.0 (up 85.15% YoY) and the FY2025 annual result came in at 1286650000.0, up 3844.96% from the prior year.
- Income from Continuing Operations climbed to 585605000.0 in Q2 2026, from 303330000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 585605000.0 in Q2 2026 to a low of 444601000.0 in Q2 2024.
- A 5-year average of 174803277.78 and a median of 170408500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 681.22% in 2024, down 318.43% in 2024.
- Tracing INCY's Income from Continuing Operations over 5 years: stood at 28461000.0 in 2022, then jumped by 606.51% to 201079000.0 in 2023, then climbed by 0.07% to 201212000.0 in 2024, then surged by 48.74% to 299279000.0 in 2025, then jumped by 95.67% to 585605000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 585605000.0 (Q2 2026), 303330000.0 (Q1 2026), and 299279000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 585.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 585.61 Mn |
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.86 Mn |
| Sep 30, 2021 | 181.74 Mn |